Hormones: Understanding Their Roles for Thyroid Optimization

Dive into the importance of thyroid optimization for hormones and their effects on health. Enhance your well-being with knowledge.

Abstract

In this educational post, I share how I evaluate, treat, and co-manage complex thyroid dysfunction using modern, evidence-based methods that align with real-world physiology and patient experience. I explain why many patients remain symptomatic despite “normal” thyroid-stimulating hormone (TSH) levels, how tissue-level thyroid signaling depends on deiodinase enzymes and mitochondrial function, and why the active hormone triiodothyronine (T3) often predicts outcomes better than TSH or T4. I outline practical algorithms for testing and treatment, compare levothyroxine (T4), liothyronine (T3), and desiccated thyroid therapy, and show how to time labs and split doses for safety and efficacy. I also describe how integrative chiropractic care fits into thyroid optimization by modulating autonomic tone, reducing pain-driven stress, and improving movement capacity. Throughout, I draw on leading research, my clinical observations from sciatica.clinic, and my professional updates, integrating nutrition, sleep, stress physiology, and neuromusculoskeletal care to restore true tissue euthyroidism.

Why Thyroid Physiology Matters

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. My commitment to thyroid care is both professional and personal. Early in life, I have treated patients who underwent total thyroid ablation and have lived for decades without native thyroid function. I have heard and felt the physiological weight of profound hypothyroidism—when my TSH exceeded 150 mIU/L during diagnostic withdrawal phases—and I bring that perspective into my care for thousands of patients.

In my integrative chiropractic practice, I have repeatedly seen a disheartening pattern: patients with “normalized” TSH on levothyroxine (LT4) who still struggle with persistent symptoms. Many describe classic hypothyroid effects such as debilitating fatigue, cold intolerance, constipation, weight gain, brain fog, slowed cognition, hair thinning, dry skin, low mood or depression, muscle weakness, and exercise intolerance. Others present with disruptive hyperthyroid manifestations, including unintended weight loss despite increased appetite, heat intolerance, anxiety or irritability, rapid heartbeat or palpitations, diarrhea, tremors, restlessness, insomnia, and excessive sweating.

That disconnect drove me to refine a physiology-first approach that prioritizes tissue-level thyroid signaling over mere lab normalization. By incorporating precise chiropractic adjustments to optimize spinal alignment and autonomic nervous system function, I help support better endocrine regulation and close the gap between lab values and real-life vitality.

Across clinical settings—including my work highlighted on sciatica—in the clinic and on my professional page, I have learned that optimizing free T3, stabilizing autonomic tone, and correcting metabolic barriers consistently lead to better function and quality of life.

Thyroid Physiology 101: From the HPT Axis to the Cell

The thyroid system is the body’s metabolic conductor. The hypothalamus produces TRH, the pituitary releases TSH, and the thyroid secretes mainly T4 with some T3. Most active T3 is produced in peripheral tissues by deiodinases:

• D1 (liver, kidney, thyroid): Converts T4 to T3 and is sensitive to inflammation, stress, toxins, insulin resistance, and caloric restriction (Bianco & da Conceição, 2018).
• D2 (brain, pituitary, brown adipose): Maintains local T3 for neuroendocrine control; the pituitary “sees” adequate T3 even when other tissues are low (Bianco & Kim, 2006).
• D3 (placenta, fetal tissues, illness states): Inactivates T4 to reverse T3 (rT3) and T3 to T2; upregulated in chronic stress and illness (Fliers et al., 2014).

Why does this matter? Because TSH is a central, not a peripheral, readout. In treated patients, the pituitary may have sufficient T3 via D2 receptors to suppress TSH, while peripheral tissues remain T3-deficient. This explains why a patient can have a “normal” or low TSH, a normal free T4, yet a low free T3 with elevated rT3—and still feel hypothyroid (Hoermann et al., 2019; Wiersinga, 2019).

• Key point: Free T3 better reflects the bioactive hormone available to tissues. In multiple clinical contexts—cardiology, critical illness, and cognition—low T3 predicts worse outcomes even when TSH and T4 look “acceptable” (Peeters, 2017; Fliers et al., 2014).

Why Patients Stay Symptomatic With “Normal” TSH

Patients can remain symptomatic despite a normalized TSH for several reasons:

• Tissue-specific deiodinase balance: D1 downregulation and D3 upregulation reduce T3 availability while raising rT3 (Bianco & da Conceição, 2018).
• Serum vs intracellular mismatch: Serum-free T3 can be “normal” while intracellular T3 is low in stressed or inflamed tissues.
• Mitochondrial energetics: T3 drives mitochondrial biogenesis, ATP production, and thermogenesis. Low tissue T3 levels manifest as fatigue, cold intolerance, and a reduced metabolic rate (Yen, 2001).
• Set-point individuality: Each person’s optimal zone may differ within the reference range.
• Genetic variation: Polymorphisms such as DIO2 Thr92Ala can alter conversion and symptom response (Panicker et al., 2009).

When this physiology is understood, the “TSH-is-enough” mindset gives way to a more nuanced, patient-centered approach.

Testing That Matches Physiology

When symptoms persist on LT4, I expand testing beyond TSH:

• Free T3, free T4, and reverse T3 to evaluate active signaling and inactivation pathways.
• Thyroid antibodies (TPO, Tg) to identify autoimmune drivers.
• Micronutrients critical for hormone synthesis/activation: iron and ferritin, selenium, zinc, vitamin D, B12, folate.
• Metabolic and inflammatory markers: lipids, A1c/insulin (HOMA-IR), hs-CRP, liver enzymes.
• Sleep and stress: apnea risk, cortisol rhythm, HRV when available.
• GI assessment, when indicated, for dysbiosis, SIBO, and bile flow, as the gut-liver-thyroid axis shapes conversion and clearance (Mantovani et al., 2018).

I also standardize lab timing for T3-containing regimens. Because oral T3 peaks 1–2 hours post-dose and declines over 4–8 hours, I draw labs 5–6 hours after the morning dose to capture a representative mid-curve value (Jonklaas et al., 2014). This reduces misinterpretation of transient peaks and makes visits comparable over time.

Treatment Principles: Restoring Tissue-Level Thyroid Signaling

My treatment aims to deliver the right hormone, in the right amount, to the right tissues, at the right time, while removing barriers to conversion.

• Address the terrain

• • Reduce inflammation and insulin resistance through protein-forward, minimally processed nutrition, omega-3s, and fiber.
  • Improve sleep and treat sleep apnea, which strongly impair thyroid and weight outcomes.
  • Replete selenium, zinc, iron/ferritin, vitamin D, and B12 to support deiodinases and thyroid peroxidase.
  • Manage stress physiology with HRV training, breathing practices, and pacing to reduce D3 upregulation.

• Optimize hormone replacement
  • Many patients thrive on LT4 monotherapy, especially when conversion is robust.
  • If free T3 remains low-normal or rT3 is elevated with persistent symptoms, I consider:

• • • LT4 + LT3 in low, split doses (e.g., 2.5–5 mcg BID) to smooth peaks and better match diurnal physiology (Jonklaas et al., 2014).
    • Desiccated thyroid extract (DTE/NDT) in selected patients who prefer or respond better to a fixed T4:T3 profile, titrating cautiously and monitoring labs and vitals (Hoang et al., 2013).

• • I avoid unnecessary TSH suppression in non-cancer patients due to bone and cardiac risks, while coordinating individualized targets for thyroid cancer survivors in line with consensus guidelines (Haugen et al., 2016).
• Monitor what matters

• • Reassess free T3, free T4, and rT3 after dose changes.
  • Track heart rate, blood pressure, HRV, sleep quality, bowel motility, mood, cognition, and exercise tolerance.
  • Time labs consistently 5–6 hours post-dose in T3-containing regimens for apples-to-apples comparisons.

Why T3 Often Drives Clinical Outcomes

The heart, brain, and mitochondria “read” T3 as the immediate metabolic signal. Multiple lines of evidence show that low free T3 correlates with worse outcomes in heart failure, acute coronary syndromes, stroke, and critical illness, whereas TSH and T4 are less predictive (Iervasi et al., 2003; Fliers et al., 2014; Peeters, 2017). Mechanistically, T3 supports:

• Cardiac inotropy and lusitropy via calcium handling and SERCA2a expression.
• Mitochondrial oxidative phosphorylation and ATP generation.
• Endothelial function and microcirculatory flow.
• Neurotransmission and synaptic plasticity, with relevance in mood and cognition.

Clinically, this is why patients often report warmer hands, clearer thinking, improved stamina, and better bowel function when free T3 moves from the lower to the mid–upper reference percentiles, under careful monitoring.

Thyroid Dysfunction-Video

Practical Dosing and Lab-Timing Strategies

I match pharmacology to physiology:

• Liothyronine (T3) has a short half-life and a quick peak. I favor BID dosing to flatten peaks and reduce palpitations or jitteriness.
• With DTE, dividing the daily dose (morning and early afternoon) often yields steadier energy and cognition.
• When adding T3 to LT4, I typically reduce LT4 by 12.5–25 mcg and add 2.5–5 mcg of T3 BID, then reassess symptoms and mid-curve labs at 4–6 weeks.
• If wearables show HR spikes 1–3 hours post-dose, I redistribute dosing rather than simply reducing the total dose. I also check caffeine timing, hydration, pain flares, and sleep—common confounders of “hyper” sensations.

Documenting off-label T3 use clearly—indication, response, dosing, and safety monitoring—supports high-quality, transparent care (Biondi & Wartofsky, 2014).

Integrative Chiropractic Care: Aligning Endocrine and Autonomic Systems

As a chiropractor and advanced practice nurse, I see daily how autonomic balance, pain, and movement capacity shape thyroid symptom expression and treatment tolerance. Integrative chiropractic care complements endocrine optimization by:

• Modulating sympathetic overdrive and enhancing vagal tone through evidence-informed spinal manipulation, soft-tissue therapy, and neuromuscular reeducation. A lower-stress tone eases the cortisol burden, supports D1 activity, and tempers D3, improving T3 availability.
• Improving biomechanics and microcirculation. Better rib and thoracic mobility enhances chest wall mechanics and oxygen delivery, synergizing with T3-driven mitochondrial ATP production.
• Reducing nociceptive input. Chronic pain is a metabolic stressor; treating pain sources lessens neuroendocrine strain and supports thyroid conversion.
• Reinforcing behavioral anchors. With each visit, I re-coach sleep, breathing, and movement habits that stabilize physiology.

In my clinical observations at the sciatica clinic and in professional updates, patients whose thyroid therapy is coordinated with chiropractic-directed movement and breathing strategies report faster improvements in energy, less constipation, and better weight trajectories compared with hormone-only care.

The Gut-Liver-Thyroid Axis and Micronutrients

The liver is a primary site of T4-to-T3 conversion; NAFLD reduces deiodinase activity and T3 availability (Mantovani et al., 2018). The microbiome affects bile acids and metabolic signaling, while constipation from low T3 worsens dysbiosis and toxin recirculation. My approach:

• Support bile flow and motility with fiber diversity, magnesium, bitters, and targeted probiotics.
• Screen and treat SIBO/dysbiosis when indicated.
• Correct iron deficiency (aiming for ferritin >50–70 ng/mL in menstruating patients) and maintain selenium and zinc sufficiency to facilitate hormone synthesis and conversion.
• Personalize iodine intake with selenium support; in autoimmunity, repletion must be careful and monitored.

When these fundamentals are addressed, I often see reduced dose requirements and improved symptom stability.

Clinical Algorithm: From Assessment to Optimization

• Foundational assessment

• • Detailed history: symptom clusters, weight trajectory, menstrual/testosterone history, medications, iodine exposure.
  • Labs: TSH, free T4, free T3, rT3, TPO/Tg antibodies, ferritin/iron studies, B12/folate, vitamin D, selenium, zinc, A1c/insulin, lipids, hs-CRP, liver enzymes.
  • Comorbidities: sleep apnea risk, NAFLD, insulin resistance, depression/anxiety, GI symptoms.
  • Musculoskeletal screen: pain generators, joint restrictions, breathing pattern, posture, autonomic load.

• Initial interventions

• • Titrate LT4 to relieve symptoms with TSH in the target range and free T4 mid-reference.
  • Implement a protein-forward, anti-inflammatory nutrition plan; begin resistance and aerobic training scaled to pain and capacity.
  • Begin chiropractic care to address segmental dysfunction and sympathetic overdrive; integrate breathing retraining.

• Reassessment at 6–8 weeks

• • If symptoms persist with low-normal free T3 or elevated rT3, consider adding T3 (2.5–5 mcg BID) or a cautious DTE trial, with shared decision-making.
  • Address sleep apnea, cortisol dysregulation, and dysbiosis.

• Advanced considerations

• • Suspected DIO2 polymorphism or tissue-level hypothyroidism: justify careful T4+T3 combination therapy.
  • Cardiometabolic risk: treat insulin resistance; consider GLP-1/GIP agents when indicated; and recheck thyroid dosing, as weight changes alter requirements.
  • Safety: Avoid unnecessary TSH suppression; monitor bone density and rhythm in at-risk patients.

• Long-term maintenance

• • Aim for stable energy, thermoregulation, cognition, bowel function, and activity tolerance, with free T3 in a patient-centered optimal zone and TSH appropriate to the clinical context.
  • Keep protocols as simple as possible while meeting physiologic needs.

What I See in Practice

Across patient cohorts highlighted at sciatica. clinic and in my professional updates, several patterns recur:

• Patients on long-standing LT4 monotherapy with low-normal free T3 levels frequently improve with small additions of LT3 or carefully titrated DTE (Hoang et al., 2013).
• Chronic constipation often resolves with thyroid normalization but responds best when paired with mobility, diaphragmatic breathing, and mineral/fiber repletion.
• Weight outcomes improve when hormone optimization coincides with progressive resistance training, better sleep, and the treatment of apnea.
• Patients with high pain burden progress more slowly until nociceptive drivers are reduced through integrative chiropractic and rehabilitation.

These observations support a simple truth: the endocrine, neural, and biomechanical systems function as a network. Treat the network, and outcomes improve.

Putting It All Together

• Focus on the bioactive hormone: free T3 often correlates best with how patients feel and function.
• Use TSH as a screen, not as the sole determinant of euthyroidism in treated patients.
• Consider combination therapy or DTE for persistent symptoms with low-normal free T3 or high rT3, using split dosing to flatten peaks and improve tolerability.
• Standardize lab timing (5–6 hours post-dose) for T3-containing regimens to ensure reliable, actionable data.
• Integrate chiropractic care to reduce sympathetic load, improve sleep and movement, and enhance metabolic flexibility.
• Track outcomes that matter: energy, cognition, pain, exercise capacity, HRV, and cardiometabolic markers—not just lab ranges.

My north star is restoring tissue-level thyroid signaling safely and sustainably, while aligning the autonomic and musculoskeletal systems to support the endocrine axis. In my experience, this integrated, evidence-guided model helps patients recover faster, feel better, and live more fully.

References

• American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer (Haugen, B. R., et al., 2016). Thyroid, 26(1), 1–133. https://doi.org/10.1089/thy.2015.0020
• Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: A randomized, double-masked, crossover study (Hoang, T. D., et al., 2013). Journal of Clinical Endocrinology & Metabolism, 98(5), 1982–1990. https://doi.org/10.1210/jc.2012-4107
• Guidelines for the treatment of hypothyroidism (Jonklaas, J. et al., 2014). Thyroid, 24(12), 1670–1751. https://doi.org/10.1089/thy.2014.0028
• Deiodinases: Implications of the local control of thyroid hormone action (Bianco, A. C., & Kim, B. W., 2006). Physiological Reviews, 86(3), 967–1019. https://doi.org/10.1152/physrev.00027.2005
• The deiodinase trio and thyroid hormone signaling (Bianco, A. C., & da Conceição, R. R., 2018). Physiological Reviews, 98(3), 1075–1105. https://doi.org/10.1152/physrev.00030.2017
• American Thyroid Association guide to investigating thyroid hormone economy and action in rodent and cell models (Bianco, A. C., et al., 2019). Thyroid, 29(6), 790–833. https://doi.org/10.1089/thy.2018.0682
• Recent advances in thyroid hormone regulation: Toward a new paradigm for optimal diagnosis and treatment (Hoermann, R. et al., 2019). Frontiers in Endocrinology, 10, 706. https://doi.org/10.3389/fendo.2019.00706
• Subclinical hypothyroidism (Peeters, R. P., 2017). New England Journal of Medicine, 376(26), 2556–2565. https://doi.org/10.1056/NEJMcp1611144
• Thyroid function in critically ill patients (Fliers, E., Wiersinga, W. M., & Boelen, A., 2014). Nature Reviews Endocrinology, 10(3), 164–174. https://doi.org/10.1038/nrendo.2013.251
• Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients (Gullo, D. et al., 2011). PLoS ONE, 6(8), e22552. https://doi.org/10.1371/journal.pone.0022552
• Physiological and molecular basis of thyroid hormone action (Yen, P. M., 2001). Endocrine Reviews, 22(4), 476–501. https://doi.org/10.1210/edrv.22.4.0435
• Thyroid hormone and nonalcoholic fatty liver disease: A cross-talk (Mantovani, A. et al., 2018). Metabolism, 84, 22–35. https://doi.org/10.1016/j.metabol.2017.12.005
• Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination T4/T3 therapy in patients with hypothyroidism (Panicker, V. et al., 2009). Journal of Clinical Endocrinology & Metabolism, 94(5), 1623–1629. https://doi.org/10.1210/jc.2008-1301
• Paradigm shifts in thyroid hormone replacement therapies (Wiersinga, W. M., 2019). Nature Reviews Endocrinology, 15(7), 413–425. https://doi.org/10.1038/s41574-019-0197-y
• The clinical significance of subclinical thyroid dysfunction (Biondi, B., & Cooper, D. S., 2008). Endocrine Reviews, 29(1), 76–131. https://doi.org/10.1210/er.2006-0043
• Low T3 syndrome: A strong prognostic predictor of death in patients with heart disease (Iervasi, G. et al., 2003). Circulation, 107(5), 708–713. https://doi.org/10.1161/01.CIR.0000048124.64204.3F

SEO tags: thyroid optimization, hypothyroidism treatment, free T3, reverse T3, TSH limitations, levothyroxine vs desiccated thyroid, combination T4 T3 therapy, deiodinase enzymes, mitochondrial metabolism, autonomic balance, integrative chiropractic care, gut liver thyroid axis, sleep apnea and thyroid, adaptive thermogenesis, evidence-based functional medicine, Dr. Alexander Jimenez DC APRN, sciatica clinic